Drugs / VZVOka
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02514018 | Sep 2015 → Jan 2017 | — | University of Toronto | Unknown | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VZVOka | “Participants receive a single dose of a commercial live-attenuated VZVOka vaccine at either week 0 (n=22) or at week 12 (n=22) of the study” PMID 28939581 ↗ Sep 2017 |
| Known as | VZVOka vaccine | “Adult Kenyan VZV-seropositive women (n = 44) received a single dose of the live zoster VZVOka vaccine.” PMID 29800309 ↗ Sep 2018 |